Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CORT and other ETFs, options, and stocks.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
500
Employees500
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
500
Employees500

CORT Key Statistics

Market cap
8.34B
Market cap8.34B
Price-Earnings ratio
91.18
Price-Earnings ratio91.18
Dividend yield
Dividend yield
Average volume
512.82K
Average volume512.82K
High today
$84.50
High today$84.50
Low today
$78.63
Low today$78.63
Open price
$79.60
Open price$79.60
Volume
201.50K
Volume201.50K
52 Week high
$117.33
52 Week high$117.33
52 Week low
$49.00
52 Week low$49.00

Stock Snapshot

Corcept Therapeutics(CORT) stock is priced at $78.90, giving the company a market capitalization of 8.34B. It carries a P/E multiple of 91.18.

On 2025-11-29, Corcept Therapeutics(CORT) stock moved within a range of $78.63 to $84.50. With shares now at $78.90, the stock is trading +0.3% above its intraday low and -6.6% below the session's peak.

Trading volume for Corcept Therapeutics(CORT) stock has reached 201.5K, versus its average volume of 512.82K.

The stock's 52-week range extends from a low of $49.00 to a high of $117.33.

The stock's 52-week range extends from a low of $49.00 to a high of $117.33.

CORT News

Simply Wall St 14h
Corcept Therapeutics: Assessing Valuation After Revenue Outlook Revision and Growth in Korlym Prescriptions

Corcept Therapeutics (CORT) has adjusted its revenue outlook for 2025, citing capacity constraints with a previous specialty pharmacy vendor. This adjustment co...

Corcept Therapeutics: Assessing Valuation After Revenue Outlook Revision and Growth in Korlym Prescriptions
The Motley Fool 1d
Corcept Q3 2025 Earnings Call Transcript

Image source: The Motley Fool. Tuesday, Nov. 4, 2025 at 7:26 p.m. ET Call participants Chief Executive Officer — Joseph K. Belanoff Chief Business Officer — Ga...

Corcept Q3 2025 Earnings Call Transcript
TipRanks 4d
Corcept Therapeutics: Poised for Growth with Relacorilant’s Launch and Strong Market Positioning

Analyst Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Corcept Therapeutics and keeping the price target at $145.00. TipRanks Black Frid...

More CORT News

Simply Wall St 5d
Is Corcept Therapeutics Fairly Priced After Recent Partnership and 54.7% Share Surge in 2025?

Wondering if Corcept Therapeutics is really worth its recent buzz, or if the market might be missing something about this fast-growing biotech? You are not alon...

Is Corcept Therapeutics Fairly Priced After Recent Partnership and 54.7% Share Surge in 2025?

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.